The American Society of Clinical Oncology (ASCO) annual meeting, which starts later this week in Chicago, is closely watched by analysts and investors alike. Favorable data presented at the event can advance a company's stock valuation significantly. Equally, candidate cancer therapies that do not live up to expectations will see their developers face the ire of investors. Read More
